Two examples, erdafitinib (FGFR inhibitor) and sotorasib (KRAS G12C inhibitor) impaired YY1 expression in genotype-matched bladder cancer cell line RT112 and pancreatic cancer cell line MIA PaCa-2, respectively (Fig. 3F). Here, YY1 is linked to urinary bladder carcinoma.